Funding for this research was provided by:
Research Training Scholarship
Monash University
Article History
Received: 29 May 2023
Revised: 30 August 2023
Accepted: 31 August 2023
First Online: 11 September 2023
Declarations
:
: Julie Stout has served on Scientific Advisory Boards for Spark Therapeutics and Teva-Australia within the past three years. Although these ad boards were focused on HD, neither focused on depression, which is the topic of the current manuscript. Julie Stout also serves in an ongoing role as a director of the company Zindametrix, which provides services to pharmaceutical companies to facilitate the implementation of cognitive assessment in Huntington's disease clinical trials. Several of these trials have been ongoing throughout the time of the research reported in this paper, however, none of the trials are focused on depression in HD, and therefore are not considered a conflict of interest for the work reported in the manuscript. Julie Stout has provided paid consulting services to Sage Therapeutics related to HD but not directly related to the work presented in this paper. Finally, Julie Stout receives an annual honorarium for her services as the Chair of the Scientific Oversight Committee of the global Enroll-HD study. Again, this role is not in conflict with or related to the contents of the report.
: The Monash University Human Research Ethics Committee (MUHREC) approved this study (MUHREC ID: 23043). All participants provided written informed consent in accordance with the Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.